Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × fludarabine × Dermatologic × Clear all

Phase

Phase 1 32 Phase 2 27 Phase 1/2 16 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 43 Lymphoid 32 Myeloid 8 Plasma cell 5 Classical hematology 2 Sarcoma 1 Other neoplasm 1 Dermatologic 1

Conditions

Interventions

Dacarbazine 24 Nivolumab 21 pembrolizumab 18 Ipilimumab 16 3-ingenyl angelate 11 Interferon-alpha 10 Imiquimod 10 trametinib 8 Temozolomide 8 dabrafenib 7 aldesleukin 7 Vemurafenib 7 Photochemotherapy 7 methyl 5-aminolevulinate 6 cemiplimab 6 Radiotherapy 6 Introns 6 Interferon alpha-2 6 Fluorouracil 6 Aminolevulinic Acid 6 Surgical Procedures, Operative 5 Melphalan 5 Interleukin-2 5 Cisplatin 5 binimetinib 4 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Gels 4 Diclofenac 4 Chemotherapy, Adjuvant 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02278887 2025-03-10

TIL

The Netherlands Cancer Institute

Phase 3 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡